Peter Greenleaf News Today

/PRNewswire/ -- Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia...

Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.07464, expectations were $-0.17.

Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and...

In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. , today announced several initiatives to improve understanding of the seriousness of lupus nephritis and the need for frequent...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2023 Earnings Call Transcript February 15, 2024 Aurinia Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.19 EPS, expectations were $-0.18. AUPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Aurinia […]

Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers and will embark on share buybacks and cost...

Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively $350.7 million of...

A survey of North American equities heading in both directions

Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To Know:

Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and...